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Abstract Juvenile neuronal ceroid lipofuscinosis, or Batten dis-
ease, is an autosomal recessive disorder characterized by pro-
gressive loss of motor and cognitive functions, loss of vision,
progressively severe seizures, and death. The disease is associ-
ated with mutations in the gene CLN3, which encodes a novel
438 amino acid protein, the function of which is currently un-
known. Protein secondary structure prediction programs suggest
that the CLN3 protein has ¢ve to seven membrane-spanning
domains (MSDs). To distinguish among a number of hypothet-
ical models for the membrane topology of CLN3 we used in
vitro translation of native, Flag epitope-labeled and glycosyla-
tion site-mutated CLN3 protein in the presence or absence of
canine pancreatic microsomes. These were immunoprecipitated
using antibodies speci¢c for Flag or peptide sequences within
CLN3 or left untreated. The results indicate that CLN3 con-
tains ¢ve MSDs, an extracellular/intraluminal amino-terminus,
and a cytoplasmic carboxy-terminus.
0 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Juvenile neuronal ceroid lipofuscinosis (JNCL), or Batten
disease, is one form of the neuronal ceroid lipofuscinoses
(NCL), a collection of at least eight inherited neurodegenera-
tive disorders with similar pathological features. JNCL is the
most common inherited neurodegenerative disease in children,
with an annual incidence from 1/25 000 to 1/40 000 live births
[1,2]. The disease is inherited in an autosomal recessive pat-
tern. Symptoms typically appear between ages 5 and 8, and
include vision loss, gradual deterioration in motor and cogni-
tive skills, changes in behavior, and progressively severe sei-
zures. Over a period of 10^20 years this process inexorably
culminates in persistent vegetative state and death. At this
time, clinical interventions are limited to amelioration of
symptoms and supportive care. No cure exists, and our under-
standing of the molecular pathogenesis of the disease remains
immature despite a considerable amount of study.
JNCL is caused by defects in a recently discovered gene
called CLN3, which is located on chromosome 16p12.1 [2].
The CLN3 gene encodes a novel 438 amino acid protein
(CLN3) the function of which is currently unknown. Homo-
logs have been identi¢ed in dogs, mice, yeast, Drosophila, and
nematodes, and the amino acid sequence of CLN3 appears to
be highly conserved in evolution [3]. In most cases of JNCL
the inherited defect is a 1.02 kb deletion of genomic DNA,
resulting in a truncation of CLN3 such that the resultant
protein contains the original 153 N-terminal residues followed
by 28 novel amino acids [2,4].
In a¡ected individuals, mutations of CLN3 result in patho-
logic intracellular inclusions in neurons and other cells of the
body. Lysosomal accumulation of auto£uorescent lipids (ce-
roid and lipofuscin) and high concentrations of a mitochon-
drial protein, ATP synthase subunit C, have been reported
[5,6]. Recent immuno£uorescence studies have shown that
the predominant intracellular destination of nascent CLN3
is the lysosome [7^10].
As we begin to learn more about CLN3, the necessity of
determining the structure of the protein becomes increasingly
apparent. Clues to the function of CLN3 may be gained by
knowing how CLN3 is distributed in the membrane, and
which amino acid residues are accessible for interaction with
cytoplasmic or non-cytoplasmic proteins. Computer-generated
models of secondary structure suggest a transmembrane pro-
tein with between ¢ve and seven membrane-spanning domains
(MSDs). Six of the membrane domains are scored as being
highly likely by the PSORT prediction program [11], and
some studies of the CLN3 gene have assumed a six-MSD
model with the C-terminus and N-terminus both located in
the extracellular milieu [12]. To date no empirical evidence to
support the six-MSD model has been pro¡ered.
To address the structure of CLN3, we have made use of the
fact that incorporation of proteins into microsomes (endoplas-
mic reticulum (ER) membranes) protects regions of the pro-
tein from recognition by antibodies and that glycosylation
activity only takes place on the luminal side of microsomes.
We have utilized immunoprecipitation with membrane-bound
CLN3 protein produced by transcription and translation in
vitro and glycosylation scanning procedure to determine
whether various epitopes lie within or outside of the ER mem-
brane. Our data show that CLN3 is a type IIIB protein, with
¢ve MSDs, an intraluminal amino-terminus, and a cytoplas-
mic carboxy-terminus.
2. Materials and methods
2.1. Construction of Flag-labeled proteins
The plasmids used to examine CLN3 structure were created by
altering portions of the CLN3 coding sequence from the plasmids
pRSV-CLN3, pAdRSV-CLN3-Flag and pGEX-CLN3 [9]. The plas-
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mid pCDNA3.1(+)Zeo was obtained from Invitrogen (Carlsbad, CA,
USA). The plasmid pAdRSV-CLN3-Flag contains the CLN3 gene
with an exogenous Flag epitope (encoding the amino acid sequence
DYKDDDDK) inserted just distal to the carboxy-terminus; hence-
forth it will be referred to as CLN3-F438. CLN3 and CLN3-F438 DNA
sequences were subcloned into pCDNA3.1Zeo from pRSV-CLN3 and
pAdRSV-CLN3-Flag, respectively, by restriction endonuclease diges-
tion using XbaI and NotI, followed by ligation with T4 ligase, and
transformation of DH5K Escherichia coli. The plasmids pCDNA-
CLN3-F260 and pCDNA-CLN3-F321 were prepared using polymerase
chain reaction (PCR) to introduce Flag epitopes into the CLN3 gene
at amino acids 260 and 321, respectively. Oligonucleotide sequences
are available upon request. These fragments were ligated into appro-
priately restricted pCDNA, checked by DNA sequencing, and sub-
cloned into pCDNA3.1Zeo.
2.2. Construction of glycosylation mutants
The CLN3 segment encoding the amino acids 87^438 was generated
by PCR, using as a template the whole-length CLN3 sequence, and
was ligated into EcoRI^XhoI-digested pCDNA3.1Zeo. The resultant
plasmids pCDNA-CLN3(87^483) and pCDNA-CLN3 were used as
the template for oligonucleotide-directed mutagenesis which converts
the Asn codon in the glycosylation site Asn-310 to a Gln codon
(N310Q). Further mutagenesis on amino acid 199 converting Ala to
Asn (A199N) was performed on pCDNA-CLN3(87^483)N310Q. The
mutagenesis was done with a kit from Stratagene (La Jolla, CA,
USA).
2.3. In vitro transcription and translation
Di¡erent plasmids were transcribed and translated in vitro in the
presence or absence of canine pancreatic microsomes using a T7-
coupled reticulocyte lysate system (TNT-T7; Promega, Madison,
WI, USA). Translated proteins were labeled by metabolic incorpora-
tion of [35S]methionine (1000 Ci/mmol) purchased from NEN (Bos-
ton, MA, USA).
2.4. Immunoprecipitation of CLN3 from intact microsomes
The antibodies Q516 and Q438 were generated by DNA immuniza-
tion, as described in [10], and recognize peptides corresponding, re-
spectively, to amino acids 2^18 and 250^264 of CLN3. The reaction
mixture (40 Wl) from in vitro transcription and translation was diluted
with 500 Wl of dilution bu¡er (50 mM Tris, 150 mM NaCl, 5 mM
EDTA, and 0.2 WM aprotinin) and incubated with 2 Wg anti-CLN3
antibody (Q516 or Q438) for 4 h at 4‡C. Membranes were isolated by
centrifugation at 70 000 rpm for 30 min and resuspended in 500 Wl
dilution bu¡er containing 1% NP-40. Reactions without microsomal
membranes did not undergo this initial ultracentrifugation step. The
samples were then mixed with 100 Wl of immobilized protein A
(Pierce, Rockford, IL, USA) for 1 h at 4‡C and the beads were
collected by centrifugation at 14 000 rpm for 2 min. The beads were
washed twice with dilution bu¡er containing 1% NP-40 and once with
dilution bu¡er alone. After the last wash, the pelleted beads were
resuspended in 50 Wl of 6ULaemmli bu¡er. The samples were resolved
on a 4^20% sodium dodecyl sulfate^polyacrylamide gel electrophore-
sis (SDS^PAGE) gradient gel, ¢xed, dried at 80‡C under vacuum, and
analyzed by autoradiography.
2.5. Immunoprecipitation of Flag constructs from intact microsomes
The plasmids pCDNA-CLN3, pCDNA-CLN3-F260, pCDNA-
CLN3-F321 and pCDNA-CLN3-F438 were transcribed and translated
in vitro as described above. Control plasmids were KRENaC-FCterm
and KRENaC-FEC (generously provided by Peter Snyder, University
of Iowa, Iowa City, IA, USA), which encode Flag-labeled membrane-
bound polypeptides in which the Flag epitope is located, respectively,
on the cytosolic side or intraluminal side of the membrane [13]. The
reaction mixture (40 Wl) was diluted with 500 Wl of dilution bu¡er and
incubated with 2 Wg anti-Flag M2 antibody for 4 h at 4‡C. Isolation
of microsomal membranes and immunoprecipitation were performed
as described above.
3. Results
3.1. Sequence analysis of CLN3
The Batten disease protein, CLN3, is extremely hydropho-
bic. The hydrophilicity plot in Fig. 1 [14] demonstrates several
large hydrophobic regions of greater than 15 amino acids,
indicating that CLN3 is likely be an integral membrane pro-
tein with multiple MSDs. The PSORT database [11] identi¢ed
up to seven potential MSDs in CLN3. Of these seven do-
mains, six have very strong probability scores of 33 to 37.
One of the putative MSDs (MSD 3) has a score of +0.11, and
is therefore unlikely to be a true transmembrane domain.
Several secondary protein-structure prediction programs
were used to analyze the amino acid sequence of CLN3, in-
cluding PSORT [11], nnPredict [15,16], and SSP [17] data-
bases. The program nnPredict uses a neural network to ana-
lyze an amino acid sequence for helix elements, turns, and
L-strands. The accuracy of the computational neural network
may approach 79% [15,16]. SSP has a probability of correct
prediction ranging from 0.78 to 0.82 for helices longer than
six residues and strands longer than eight residues [17]. The
previously published six-MSD model of CLN3 structure pro-
posed by Janes et al., in which both the COOH- and NH2-
termini are intraluminal (in the lysosome) or cytoplasmic (if
on the plasma membrane), corresponds to the structure pre-
dicted by PSORT if the one unlikely MSD is excluded [12].
Fig. 1. Secondary structure analyses of CLN3. Kyte^Doolittle plot of the primary sequence of CLN3, showing domains of the protein which
are hydrophobic.
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3.2. Localization of the amino-terminus by immunoprecipitation
and glycosylation mutagenesis
CLN3 protein was prepared by in vitro transcription and
translation and immunoprecipitated with Q516, an antibody
which recognizes an epitope within the amino-terminal 20
amino acids of CLN3. Electrophoresis of the translated prod-
uct revealed a peptide with a molecular weight of 43^45 kDa
(Fig. 2A, lane 1). When translated in the presence of micro-
somal membranes, intraluminal epitopes become inaccessible
to antibodies; this space is equivalent to the lumen of the ER,
and as such is equivalent to the lysosomal lumen or the extra-
cellular space. Fig. 2A, lane 2 is representative of three inde-
pendent experiments and shows that Q516 did not precipitate
CLN3 from intact microsomes. Subsequent puri¢cation of the
supernatant-containing unprecipitated microsomes indicated
that the protein was properly translated and incorporated
into the membrane (Fig. 2A, lane 3). The molecular weight
of translated CLN3 increases slightly, re£ecting the addition
of N-linked oligosaccharide moieties during post-translational
processing in the microsomes.
Additional control experiments con¢rmed that the lack of
immunoprecipitation by Q516 was due to inaccessibility of the
antigen rather than a technical di⁄culty with the experiments.
Two plasmids encoding Flag-epitope-containing proteins were
tested. These plasmids contain the coding sequence for the
K subunit of the amiloride-sensitive sodium channel from
rats (KRENaC). The plasmid KRENaC-FEC contains a Flag
epitope at the amino-terminus, which is located in the extra-
cellular milieu and thus protected from precipitation by Flag
antibody. The plasmid KRENaC-FCterm contains Flag at the
carboxy-terminus, which is cytoplasmic and therefore accessi-
ble to the antibody [13]. The representative data shown in Fig.
2B replicate the published data and show that Flag M2 anti-
body precipitates both proteins. However, only KRENaC-
Fig. 2. The amino-terminus of CLN3 is intraluminal. A: CLN3 was translated in vitro in a cocktail containing [35S]Met. Translation occurred
in the absence (lane 1) or presence (lanes 2 and 3) of microsomes. After translation, Q516 antibody (lanes 1 and 2) was added and precipitates
isolated (see Section 2). Residual microsomal membranes were collected by centrifugation to con¢rm incorporation of CLN3 into membranes
(lane 3). Immunoprecipitates and non-precipitated microsomes were resolved by SDS^PAGE and visualized by autoradiography. B: Control
study demonstrating the validity of the approach as originally described by Snyder et al. [13]. Proteins were translated in a [35S]Met-containing
cocktail, in the absence (lanes 1 and 2) or presence (lanes 3 and 4) of microsomes. Translated products were immunoprecipitated with anti-
Flag antibodies, and immunocomplexes dissociated and fractionated on SDS^PAGE. Lanes 1 and 3 are representative of translated ENaC sub-
units with Flag epitopes located in extracellular domains. Lanes 2 and 4 are representative of translated ENaC subunits with Flag placed in a
cytoplasmic region. C: pCDNA-CLN3 (lanes 1 and 2) and pCDNA-CLN3N310Q (lanes 3 and 4) were translated in vitro in a cocktail contain-
ing [35S]Met in the absence (lane 1and 3) or presence (lanes 2 and 4) of microsomes.
Fig. 3. The carboxy-terminus of CLN3 is cytoplasmic. CLN3 was
translated in vitro in a cocktail containing [35S]Met. Translation oc-
curred in the absence (lane 1) or presence (lanes 2 and 3) of micro-
somes. After translation, anti-Flag antibody (lanes 1 and 2) was
added and precipitates isolated. Residual microsomes were isolated
by centrifugation. Translated products were fractionated by SDS^
PAGE and then visualized by autoradiography.
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FCterm could be precipitated from microsomes (compare Fig.
2B, lanes 3 and 4).
We next asked if the glycosylation pattern of CLN3 in the
presence of microsomes was retained when the residual glyco-
sylation site at Asn310 was removed, but the three potential
glycosylation sites at the amino-terminus of CLN3, Asn-46,
Asn-49, and Asn-71 were retained. If the amino-terminus was
cytoplasmic, the N310Q mutation would ablate glycosylation-
induced shifts. On the contrary, if the amino-terminus was
intraluminal, there should be no or little alteration in the
band shift compared to wild-type CLN3. As seen in Fig.
2C, there was no change in the glycosylation pattern between
wild-type CLN3 and N310Q, con¢rming that the amino-ter-
minus is intraluminal.
3.3. Localization of the carboxy-terminus by
immunoprecipitation
The plasmid pCDNA-CLN3-F438 contains the CLN3 gene
with a Flag epitope inserted between the last amino acid (res-
idue 438) and the stop codon. The six-MSD model of CLN3
predicts this region to be intraluminal. As shown in Fig. 3,
Flag M2 antibody precipitated the pCDNA-CLN3-F438 pro-
tein, thus indicating that the C-terminus is cytoplasmic. There
was no cross-reactivity between the Flag epitope and CLN3.
That the C-terminus and the N-terminus reside on opposite
sides of the membrane indicates that CLN3 has an odd num-
ber of MSDs, and therefore rules out the proposed six-MSD
model.
3.4. Localization of other regions of CLN3 by
immunoprecipitation and glycosylation mutagenesis
To di¡erentiate between the most likely remaining models
(the ¢ve-MSD and seven-MSD models) we focused upon
three other regions of CLN3. In the seven-MSD model, amino
acid residue 199 would be on the cytoplasmic side of the
membrane, amino acid residues 250^260 would be intralumi-
nal and amino acid residue 310 or 321 would be on the cyto-
plasmic side of the membrane. The reverse of this arrange-
ment would rule out the seven-MSD model.
A CLN3 construct lacking the three amino-terminal glyco-
sylation sites, CLN3(v1^87), was modi¢ed to contain a new
glycosylation site at residue 199. As shown in Fig. 4A, A199N
Fig. 4. A: Glycosylation site insertion and disruption localize residues 199 and 310 to the lumen. pCDNA-CLN3(v1^87) (lanes 1 and 2),
pCDNA-CLN3(v1^87)N310Q (lanes 3 and 4) and pCDNA-CLN3(v1^87)N310Q/A199N were translated in vitro in a cocktail containing
[35S]Met in the absence (lanes 1, 3 and 5) or presence (lanes 2, 4 and 6) of microsomes. B: The epitope spanning aa 250^264 of CLN3 is lo-
cated in the cytoplasm. CLN3 was translated in vitro as described in the legend to Figs. 2 and 3. Translation occurred in the absence (lane 1)
or presence (lanes 2 and 3) of microsomes. Precipitation of translated products (lanes 1 and 2) was done using anti-CLN3 antibody Q438.
C: Residue 321 of CLN3 is not cytoplasmic. CLN3-Flag321 was translated in vitro as described in the legend to Figs. 2 and 3. Translation oc-
curred in the absence (lane 1) or presence (lanes 2 and 3) of microsomes. Precipitation of translated products (lanes 1 and 2) was done using
anti-Flag antibody.
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resulted in a shift consistent with increased glycosylation, rel-
ative to protein translated in the absence of microsomes.
These data support that residue 199 is intraluminal.
The region corresponding to amino acid residues 250^260
was evaluated both by insertion of a Flag epitope and by a
recently developed antibody recognizing this region of the
native CLN3 protein. The antibody Q438, generated by
DNA immunization, recognizes a peptide corresponding to
amino acid residues 250^264 of CLN3. This antibody precipi-
tated microsomal membrane-bound CLN3 (Fig. 4B, lane 2).
The plasmid pCDNA-CLN3-F260, containing the Flag epitope
inserted between amino acids 260 and 261 of CLN3, was like-
wise immunoprecipitated by Flag M2 antibody, suggesting
that this region of the protein is cytoplasmic (data not
shown).
Finally, we con¢rmed the position of the carboxy-terminal
residues of CLN3; residue 310 by removing the endogenous
glycosylation site in CLN3(v1^87), and residue 321 by Flag
epitope insertion. As seen in Fig. 4C, CLN3-321Flag was pro-
tected by the microsomal membrane from recognition by anti-
Flag antibody. Glycosylation-scanning experiments corrobo-
rated this observation. Glycosylation was detected when
CLN3(v1^87) was translated in the presence of microsomes
(Fig. 4A, lanes 1 and 2), while no molecular weight shift was
observed in the double mutant CLN3(v1^87)N310Q (Fig. 4A,
lanes 3 and 4). Together, these experiments localize MSD 5
within the membrane, and argue against the seven-MSD mod-
el.
4. Discussion
Our studies of CLN3 indicate that it is a transmembrane
protein with an odd number of MSDs. Our ¢ndings are most
consistent with a structural model in which the protein has
¢ve domains that fully span the membrane, a cytoplasmic
carboxy-terminus, and an amino-terminus which is located
in the lumen of the ER.
The fact that the carboxy-terminus and amino-terminus lie
on opposite sides of the ER membrane rules out models of
protein structure in which there exist even numbers of MSDs.
Q516
Q438
FLAG
Q438
Q516A. C.
Q516
Q438
B. Q516
Q438
D.
321
FLAG 438
FLAG 260
FLAG 321
FLAG 438FLAG 260
FLAG 321
FLAG438
FLAG 260
FLAG 321
FLAG438FLAG 260
Fig. 5. Models for the orientation of CLN3 in the membrane. The data presented are consistent with CLN3 containing ¢ve domains which
span the entire width of the membrane. CLN3 has an intraluminal, or extracellular, amino-terminus, and a cytoplasmic carboxy-terminus. It is
possible that MSD 6 or MSD 7 could orientate within, rather than through, the membrane (panels A and B, respectively). Alternatively, MSD
6 may reside in the vesicle lumen (panel C). A fourth model can also be proposed, with MSD 7 located in the cytoplasm. This is the least fa-
vored of the four models.
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This includes the six-MSD model proposed by Janes and col-
leagues [4,12]. The ¢ve-MSD model illustrated in Fig. 5 shows
the relative locations of the six most favored MSDs (1, 2,
4^7). We conclude that MSD 3, which has a score of +0.10
and is predicted to form a relatively small L structure, is un-
likely to be a true MSD. The cumulative data on epitope
precipitation with antibodies targeted to the aa 260 (cytoplas-
mic) and aa 321 regions (intraluminal) and glycosylation scan-
ning on residues 199 (intraluminal) and 310 (intraluminal)
ruled out a seven-MSD structure and con¢rmed that MSD
5 does in fact span the membrane. Of MSDs 6 and 7, the
latter has a higher probability of being membrane-bound
than does the former. However, our data are consistent with
either one of these putative MSDs spanning the entire width
of the membrane, and the other embedded within the mem-
brane (Fig. 5A,B).
Data using viral-mediated or plasmid-based transfections to
over-express CLN3 supports our ¢ndings. Ja«rvela« et al. [8]
showed that a small amount of CLN3 is found at the plasma
membrane. In vitro tra⁄cking work in our laboratory showed
that the amino-terminus of native CLN3 is accessible to the
Q516 antibody but not to the Q438 antibody (Davidson and
Mao, unpublished observations). Furthermore, unpublished
data from phage display studies suggest the possibility of an
interaction between two regions of the CLN3. A peptide cor-
responding to amino acid residues 67^91 was used as bait and
was found to interact with peptides corresponding to amino
acids 163^215 of CLN3 (Davidson, unpublished observation).
Binding between these two regions, if con¢rmed, would re-
quire that they be located in the same compartment as is
predicted by our ¢ve-MSD model (Fig. 5).
In contrast to the previously published model of CLN3, we
have demonstrated that the C-terminal domain resides on the
cytoplasmic side of the membrane. Analysis of the amino acid
sequence of the carboxy-terminal region of CLN3 indicates
several motifs that could potentially interact with cytoplasmic
adapter complexes involved in sorting of integral membrane
proteins [18,19]. The C-terminal tail of CLN3 contains three
tyrosine-based motifs and several LL- and LI-pairs. These
motifs are found in other lysosomal membrane proteins
such as LAMP-1, LIMP-II and LAMP-2 [18^20]. Although
the LL- and LI-motifs are unlikely to be targets for adapter
protein complex binding, two of the tyrosine-based motifs, aa
378^382 and 387^391, show high sequence similarities to other
lysosomal targeting or internalization motifs [18]. The third
tyrosine-based motif, aa 370^374, lies embedded within puta-
tive MSD 7.
In addition to the 1.02 kb deletion which is present in a
majority of patients, there exist disease-causing point muta-
tions in other regions of the protein [4,21,22]. Patients who
are compound heterozygotes and have the 1.02 kb deletion
coupled with a transition mutation resulting in substitution of
phenylalanine for valine at the 330th amino acid residue
(V330F) are a¥icted with JNCL, as are compound heterozy-
gotes who have the mutation R334H. Compound heterozy-
gous patients with L101P, L170P, or E295K substitutions may
have a more protracted and less severe clinical course, featur-
ing visual loss but modest impairments of cognition and mo-
tor function [4]. Although the truncation mutant created by
the 1.02 kb genomic deletion shows defective intracellular
tra⁄cking and accumulates in the ER [8], studies to date in-
dicate that disease-causing point mutations do not grossly
disrupt tra⁄cking to the lysosome but rather CLN3 function
[10]. Interestingly, our model of CLN3 places all but one of
these point mutations within the lumen of the ER. Because
some CLN3 tra⁄cs to the cell surface (Davidson and Mao,
unpublished observations), there exists the possibility that the
CLN3 mutations may a¡ect appropriate protein^protein in-
teractions with substances in the extracellular milieu, or with
other membrane proteins. Alternatively, if CLN3 is found to
be a transport protein, presence on the cell membrane may
allow for transport of its target molecule into the cell cyto-
plasm as well as in the lysosome. Testing of these hypotheses
requires further experimentation.
In summary, the juvenile form of Batten disease, or JNCL,
is a devastating and presently incurable neurologic disease
resulting from mutations in a lysosomal integral membrane
protein with ¢ve MSDs. Our e¡orts to determine the mem-
brane structure of the protein provide a number of clues that
assist our ongoing e¡orts to delineate CLN3 function and its
role in the molecular pathogenesis of JNCL.
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